海外高增长、营收占比突破36%，海尔生物2025年营收超23亿元

Core Viewpoint - Haier Biomedical demonstrated strong resilience in its development, achieving a revenue of 2.33 billion yuan in 2025, with a year-on-year growth of 2.0% and a fourth-quarter revenue growth of 13.1% [2]. Group 1: Overseas Development - Haier Biomedical's overseas revenue reached 840 million yuan in 2025, marking a year-on-year growth of 17.9% and accounting for 36% of total revenue, an increase of 5 percentage points from 2024 [4]. - The company has seen a compound annual growth rate of over 20% in overseas revenue from 2016 to 2024, with notable growth in Europe (16.0%), Asia-Pacific (26.0%), Americas (12.2%), and Africa (17.8%) [4]. - The Eco-Drive technology developed by the company has improved efficiency by 30%, achieving the highest energy efficiency in the industry [4]. Group 2: Innovation and New Industries - New industries contributed 48.5% of total revenue in 2025, with a year-on-year growth of 8.8%, particularly driven by the smart medication sector, which grew by 18.8% [7]. - The blood technology sector also maintained double-digit growth at 14.8%, with a market share exceeding 50% in plasma collection solutions [8]. - The laboratory sector achieved a growth of 4.9%, with key products maintaining leading market shares among domestic brands [9]. Group 3: AI and Technological Advancements - AI technology has become a significant driver for Haier Biomedical, with AI-related revenue accounting for 15% of total revenue in 2025, an increase of 2.5 percentage points from 2024 [12]. - The company launched 11 new products in 2025, including fully automated cell culture workstations and automated tumor liquid robots, showcasing its commitment to innovation [11]. - Collaborations with research institutions have led to the development of advanced solutions, enhancing the company's technological capabilities and market position [11].